Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-derived exosome intrauterine injection for advanced endometriosis
IRCT20251221068398N2Phase 2Recruiting
- Sponsor
- ACECR
- Start
- Apr 2026
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of extracellular vesicles derived from Wharton's jelly mesenchymal stem cells in endometriosis, sponsored by ACECR. Primary endpoint: Safety and tolerability. Started Apr 2026; status: recruiting.
02
Drugs
extracellular vesicles derived from Wharton's jelly mesenchymal stem cells
03
Conditions
endometriosis
Beyond the preview
Go deeper on IRCT20251221068398N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251221068398N2.